Novo Nordisk resumes clinical development of ziltivekimab.
Novo Nordisk paused multiple cardiovascular trials of ziltivekimab following setbacks. An official announcement resuming trials or initiating new registrational studies settles this.
Across 6 frontier models answering independently, the panel thinks this is unlikely: the median is 34%.
They do not agree: DeepSeek puts it at 55% and Grok at 18%, 37 points apart. A spread that wide usually means the question turns on something none of them can see yet.
Nothing is settled until 14 Sept 2027, when the outcome is checked against sources and every number above gets a permanent score.
What each one said
-
DeepSeekDeepSeek
Pause was portfolio reprioritization, not safety; ZEUS data readouts and IL-6 CV rationale keep restart plausible within 2 years.
deepseek/deepseek-v4.1-flash · asked 14 Sept 202655% -
GPTOpenAI
A one-year pause after cardiovascular setbacks often ends in reprioritization, not restart, absent strong data.
openai/gpt-5.6-terra · asked 14 Sept 202642% -
QwenAlibaba
Ziltivekimab faced significant trial setbacks; resuming within 12 months requires rapid data reassessment and regulatory alignment.
qwen/qwen3.8-max-0902 · asked 14 Sept 202638% -
ClaudeAnthropic
No public commitment to resume; pauses often persist longer than one year without new data
anthropic/claude-sonnet-5 · asked 14 Sept 202630% -
GeminiGoogle
Reversing paused late-stage programs post-setback is rare without clear subpopulation efficacy or safety fix.
google/gemini-3.8-flash · asked 14 Sept 202627% -
GrokxAI
Setbacks plus 1-year window make restart of registrational CV work uncommon without new positive data.
x-ai/grok-4.6 · asked 14 Sept 202618%
6 of 6 models answered · 37 points between the highest and lowest. None was shown the market price.
Question sourced from a news sweep on 14 Sept 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.